Abstract
Purpose: Long-acting β2-agonists (LABAs) have demonstrated efficacy in patients with COPD in clinical trials. The purpose of this study was to assess the comparative efficacy of all available dosages of all LABA monotherapies using a network meta-analysis. Methods: A systematic literature review identified 33 randomized controlled trials of LABA monotherapies (salmeterol 50 μg twice daily [BID]; formoterol 12 μg BID; indacaterol 75, 150, and 300 μg once daily [OD]; olodaterol 5 and 10 μg OD, and vilanterol 25 μg OD). Clinical efficacy was evaluated at 12 and 24 weeks in terms of trough forced expiratory volume in 1 second (FEV1), transition dyspnea index focal score, St George’s Respiratory Questionnaire total score, and rate of COPD exacerbations. The relative effectiveness of all LABA monotherapies was estimated by Bayesian network meta-analysis. Results: At 12 and 24 weeks, indacaterol 300 and 150 μg OD were associated with statistically significant improvement in trough FEV1 compared to all other LABA monotherapies; vilanterol 25 μg OD was superior to formoterol 12 μg BID. At 12 weeks, indacaterol 75 μg OD was associated with significant improvement in trough FEV1 compared to formoterol 12 μg BID and olodaterol (5 and 10 μg OD); salmeterol 50 μg BID was superior to formoterol 12 μg BID and olodaterol 5 μg OD. Indacaterol 300 μg OD was also associated with significant improvement in transition dyspnea index focal score compared to all other LABAs at 12 or 24 weeks. Indacaterol 150 μg OD had significantly better results in exacerbation rates than olodaterol 5 μg and olodaterol 10 μg OD. Conclusion: Indacaterol 300 μg, followed by 150 and 75 μg, were the most effective LABA monotherapies for moderate to severe COPD.
| Language | English (US) |
|---|---|
| Pages | 367-381 |
| Number of pages | 15 |
| Journal | International Journal of COPD |
| Volume | 12 |
| DOIs | |
| State | Published - Jan 19 2017 |
Fingerprint
Keywords
- COPD
- Indacaterol
- Long-acting β2-agonists
- Network meta-analysis
- Systematic literature review
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Health Policy
- Public Health, Environmental and Occupational Health
Cite this
Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease : A network meta-analysis. / Donohue, James F.; Betts, Keith A.; Du, Ella Xiaoyan; Altman, Pablo; Goyal, Pankaj; Keininger, Dorothy L.; Gruenberger, Jean Bernard; Signorovitch, James E.
In: International Journal of COPD, Vol. 12, 19.01.2017, p. 367-381.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease
T2 - International Journal of COPD
AU - Donohue,James F.
AU - Betts,Keith A.
AU - Du,Ella Xiaoyan
AU - Altman,Pablo
AU - Goyal,Pankaj
AU - Keininger,Dorothy L.
AU - Gruenberger,Jean Bernard
AU - Signorovitch,James E.
PY - 2017/1/19
Y1 - 2017/1/19
N2 - Purpose: Long-acting β2-agonists (LABAs) have demonstrated efficacy in patients with COPD in clinical trials. The purpose of this study was to assess the comparative efficacy of all available dosages of all LABA monotherapies using a network meta-analysis. Methods: A systematic literature review identified 33 randomized controlled trials of LABA monotherapies (salmeterol 50 μg twice daily [BID]; formoterol 12 μg BID; indacaterol 75, 150, and 300 μg once daily [OD]; olodaterol 5 and 10 μg OD, and vilanterol 25 μg OD). Clinical efficacy was evaluated at 12 and 24 weeks in terms of trough forced expiratory volume in 1 second (FEV1), transition dyspnea index focal score, St George’s Respiratory Questionnaire total score, and rate of COPD exacerbations. The relative effectiveness of all LABA monotherapies was estimated by Bayesian network meta-analysis. Results: At 12 and 24 weeks, indacaterol 300 and 150 μg OD were associated with statistically significant improvement in trough FEV1 compared to all other LABA monotherapies; vilanterol 25 μg OD was superior to formoterol 12 μg BID. At 12 weeks, indacaterol 75 μg OD was associated with significant improvement in trough FEV1 compared to formoterol 12 μg BID and olodaterol (5 and 10 μg OD); salmeterol 50 μg BID was superior to formoterol 12 μg BID and olodaterol 5 μg OD. Indacaterol 300 μg OD was also associated with significant improvement in transition dyspnea index focal score compared to all other LABAs at 12 or 24 weeks. Indacaterol 150 μg OD had significantly better results in exacerbation rates than olodaterol 5 μg and olodaterol 10 μg OD. Conclusion: Indacaterol 300 μg, followed by 150 and 75 μg, were the most effective LABA monotherapies for moderate to severe COPD.
AB - Purpose: Long-acting β2-agonists (LABAs) have demonstrated efficacy in patients with COPD in clinical trials. The purpose of this study was to assess the comparative efficacy of all available dosages of all LABA monotherapies using a network meta-analysis. Methods: A systematic literature review identified 33 randomized controlled trials of LABA monotherapies (salmeterol 50 μg twice daily [BID]; formoterol 12 μg BID; indacaterol 75, 150, and 300 μg once daily [OD]; olodaterol 5 and 10 μg OD, and vilanterol 25 μg OD). Clinical efficacy was evaluated at 12 and 24 weeks in terms of trough forced expiratory volume in 1 second (FEV1), transition dyspnea index focal score, St George’s Respiratory Questionnaire total score, and rate of COPD exacerbations. The relative effectiveness of all LABA monotherapies was estimated by Bayesian network meta-analysis. Results: At 12 and 24 weeks, indacaterol 300 and 150 μg OD were associated with statistically significant improvement in trough FEV1 compared to all other LABA monotherapies; vilanterol 25 μg OD was superior to formoterol 12 μg BID. At 12 weeks, indacaterol 75 μg OD was associated with significant improvement in trough FEV1 compared to formoterol 12 μg BID and olodaterol (5 and 10 μg OD); salmeterol 50 μg BID was superior to formoterol 12 μg BID and olodaterol 5 μg OD. Indacaterol 300 μg OD was also associated with significant improvement in transition dyspnea index focal score compared to all other LABAs at 12 or 24 weeks. Indacaterol 150 μg OD had significantly better results in exacerbation rates than olodaterol 5 μg and olodaterol 10 μg OD. Conclusion: Indacaterol 300 μg, followed by 150 and 75 μg, were the most effective LABA monotherapies for moderate to severe COPD.
KW - COPD
KW - Indacaterol
KW - Long-acting β2-agonists
KW - Network meta-analysis
KW - Systematic literature review
UR - http://www.scopus.com/inward/record.url?scp=85010471710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010471710&partnerID=8YFLogxK
U2 - 10.2147/COPD.S119908
DO - 10.2147/COPD.S119908
M3 - Article
VL - 12
SP - 367
EP - 381
JO - International Journal of COPD
JF - International Journal of COPD
SN - 1176-9106
ER -